Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
Paulos GebrehiwetLisa MengStacy A RudnickiPhil SaroccoJenny WeiAndrew A WolffMichael ButznerAdriano ChioJinsy A AndrewsAngela GengeDyfrig A HughesCarlayne E JacksonNoah LechtzinTimothy M MillerJeremy M ShefnerPublished in: Journal of medical economics (2023)
showed a modest but significant benefit in health utilities and QALYs compared with placebo. Future long-term studies that include direct collection of EQ-5D-5L data will be needed to confirm our findings.ClinicalTrials.gov identifier: NCT03160898.